Barclays
BEAM icon

Barclays’s Beam Therapeutics BEAM Stock Holding History

Barclays’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$735K – 5275
2024
Q3 		$735K Buy
+30,000
New +$775K ﹤0.01% 3551
2024
Q2 		– Sell
-47,000
Closed -$1.55M – 4881
2024
Q1 		$1.55M Buy
+47,000
New +$1.46M ﹤0.01% 2775

Other funds holding BEAM

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
D.A. Davidson & Co
D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Barclays's BEAM Position: Q3 2026 in Review

Barclays increased its Beam Therapeutics (BEAM) stake by 104% in Q3 2026, buying an estimated $2.04M and bringing the position to 143,399 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Barclays first reported a position in BEAM in Q1 2022 and has held it in 19 quarters since. The position peaked at $11.6M in Q2 2025. 96 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Barclays held 143,399 shares of Beam Therapeutics worth $3.51M as of Q3 2026.
  • Barclays bought 73,180 Beam Therapeutics shares in Q3 2026, an estimated $2.04M.
  • Beam Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2238 holding.
  • Barclays first reported a position in Beam Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Beam Therapeutics position peaked at $11.6M in Q2 2025.
  • 96 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.